<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02047227</url>
  </required_header>
  <id_info>
    <org_study_id>EMR200061-005</org_study_id>
    <secondary_id>2013-003817-16</secondary_id>
    <nct_id>NCT02047227</nct_id>
  </id_info>
  <brief_title>Phase 3 Study to Evaluate the Efficacy and Safety of Pergoveris® in Assisted Reproductive Technology (ESPART)</brief_title>
  <acronym>ESPART</acronym>
  <official_title>A Phase III, Randomized, Controlled, Single-blind, Multicentre, Parallel Arm Trial to Assess the Efficacy and Safety of Pergoveris® (Follitropin Alfa and Lutropin Alfa) and GONAL-f® (Follitropin Alfa) for Multifollicular Development as Part of an Assisted Reproductive Technology Treatment Cycle in Poor Ovarian Responders, as Defined by the European Society of Human Reproduction and Embryology Criteria</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, randomized, controlled, single-blind, multicenter, parallel-arm trial to
      assess the safety and efficacy of Pergoveris® (recombinant human follicle stimulating hormone
      [r-hFSH]/recombinant human luteinising hormone [r-hLH]) and GONAL-f® for multifollicular
      development as part of an assisted reproductive technology (ART) treatment cycle in poor
      ovarian responders, as aligned with the 2011 Consensus Meeting of the European Society of
      Human Reproduction and Embryology (ESHRE) criteria.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 31, 2014</start_date>
  <completion_date type="Actual">August 31, 2015</completion_date>
  <primary_completion_date type="Actual">August 31, 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Oocytes Retrieved</measure>
    <time_frame>At approximately 34 to 38 hours after r-hCG administration (Day 113)</time_frame>
    <description>Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ongoing Pregnancy Rate</measure>
    <time_frame>70 days after embryo transfer (Day 185)</time_frame>
    <description>Ongoing pregnancy rate was defined as the percentage of subjects with a ultrasound confirmation of at least one viable fetus (positive fetal heart beat).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Live Birth Rate</measure>
    <time_frame>Approximately 180 days following ongoing pregnancy determination (Day 365)</time_frame>
    <description>Live birth rate was defined as the percentage of subjects with at least one live-born neonate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Embryo Implantation Rate</measure>
    <time_frame>35-42 days post r-hCG administration (Day 154)</time_frame>
    <description>Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Pregnancy Rate</measure>
    <time_frame>35-42 days post r-hCG administration (Day 154)</time_frame>
    <description>Clinical pregnancy rate defined as the percentage of subjects with a ultrasound confirmation of a gestational sac, with or without fetal heart activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biochemical Pregnancy Rate</measure>
    <time_frame>15 to 20 days post r-hCG administration (Day 132)</time_frame>
    <description>Biochemical pregnancy rate was defined as the percentage of subjects with a positive beta-hCG result from the serum pregnancy test.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">939</enrollment>
  <condition>Infertility</condition>
  <arm_group>
    <arm_group_label>Pergoveris®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>GONAL-f®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pergoveris®</intervention_name>
    <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.</description>
    <arm_group_label>Pergoveris®</arm_group_label>
    <other_name>r-hFSH/r-hLH</other_name>
    <other_name>Follitropin alfa/Lutropin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GONAL-f®</intervention_name>
    <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.</description>
    <arm_group_label>GONAL-f®</arm_group_label>
    <other_name>r-hFSH</other_name>
    <other_name>Follitropin alfa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Recombinant human chorionic gonadotrophin (r-hCG)</intervention_name>
    <description>On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously</description>
    <arm_group_label>Pergoveris®</arm_group_label>
    <arm_group_label>GONAL-f®</arm_group_label>
    <other_name>Ovidrel®</other_name>
    <other_name>Ovitrelle®</other_name>
    <other_name>choriogonadotropin alfa</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Poor ovarian responders according to specific criteria that are aligned with poor
             ovarian response (POR) criteria defined by the 2011 Consensus Meeting of the European
             Society of Human Reproduction and Embryology (ESHRE) as mentioned in the protocol

          -  Female subjects, less than (&lt;) 41 years of age (according to date of birth at time of
             informed consent) who are eligible for ovarian stimulation and ART treatment,
             including intracytoplasmic sperm injection (ICSI)

          -  Absence of anatomical abnormalities of the reproductive tract that would interfere
             with implantation or pregnancy

          -  Absence of any medical condition in which pregnancy is contraindicated

          -  Body mass index 18 to 30 kilogram per square meter (kg/m^2), inclusive

          -  Motile, ejaculatory sperm must be available (donated and/or cryopreserved sperm is
             allowed). Intracytoplasmic sperm injection will be allowed during this trial

          -  Minimum of 1 month without treatment with either clomiphene citrate or gonadotrophins
             prior to screening

          -  Signed and dated informed consent indicating that the subject has been informed of all
             the pertinent aspects of the trial prior to enrollment

        Exclusion Criteria:

          -  Two episodes of POR after maximal stimulation

          -  History or presence of tumors of the hypothalamus or pituitary gland

          -  History or presence of ovarian enlargement or cyst of unknown etiology, or presence of
             an ovarian cyst greater than 25 mm on the day of randomization

          -  Presence of endometriosis Grade III - IV, confirmed or suspected

          -  Presence of uni- or bilateral hydrosalpinx

          -  Abnormal gynecological bleeding of undetermined origin

          -  Contraindication to being pregnant and/or carrying a pregnancy to term

          -  History or presence of ovarian, uterine or mammary cancer

          -  Use of testicular or epididymal sperm

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>41 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck KGaA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Please contact the Merck KGaA Communication Center</name>
      <address>
        <city>Darmstadt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <results_reference>
    <citation>Humaidan P, Chin W, Rogoff D, D'Hooghe T, Longobardi S, Hubbard J, Schertz J; ESPART Study Investigators‡. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders. Hum Reprod. 2017 Mar 1;32(3):544-555. doi: 10.1093/humrep/dew360.</citation>
    <PMID>28137754</PMID>
  </results_reference>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2014</study_first_submitted>
  <study_first_submitted_qc>January 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2014</study_first_posted>
  <results_first_submitted>August 24, 2016</results_first_submitted>
  <results_first_submitted_qc>November 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 24, 2017</results_first_posted>
  <last_update_submitted>July 24, 2017</last_update_submitted>
  <last_update_submitted_qc>July 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ESPART</keyword>
  <keyword>Reproductive Techniques, Assisted</keyword>
  <keyword>Infertility</keyword>
  <keyword>Pergoveris®</keyword>
  <keyword>GONAL-f®</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorionic Gonadotropin</mesh_term>
    <mesh_term>Follicle Stimulating Hormone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at 101 sites in 15 countries.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Pergoveris</title>
          <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of recombinant human chorionic gonadotrophin (r-hCG) (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
        </group>
        <group group_id="P2">
          <title>GONAL-f</title>
          <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="462"/>
                <participants group_id="P2" count="477"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Completed Ovarian Stimulation Phase</title>
              <participants_list>
                <participants group_id="P1" count="424"/>
                <participants group_id="P2" count="440"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="318"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="144"/>
                <participants group_id="P2" count="130"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Spontaneous pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of ovarian response to stimulation</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No oocytes retrieved</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>No fertilization</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="51"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Intention to freeze all embryos</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>All embryos discarded</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All Randomized Subjects Set included all subjects who were randomized.</population>
      <group_list>
        <group group_id="B1">
          <title>Pergoveris</title>
          <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 IU rhFSH/150 IU rhLH after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
        </group>
        <group group_id="B2">
          <title>GONAL-f</title>
          <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="462"/>
            <count group_id="B2" value="477"/>
            <count group_id="B3" value="939"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.3" spread="2.9"/>
                    <measurement group_id="B2" value="38.3" spread="3.0"/>
                    <measurement group_id="B3" value="38.3" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="462"/>
                    <measurement group_id="B2" value="477"/>
                    <measurement group_id="B3" value="939"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Oocytes Retrieved</title>
        <description>Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.</description>
        <time_frame>At approximately 34 to 38 hours after r-hCG administration (Day 113)</time_frame>
        <population>Intent-to-treat (ITT) analysis set included all subjects randomized who received at least 1 dose of GONAL-f or Pergoveris.</population>
        <group_list>
          <group group_id="O1">
            <title>Pergoveris</title>
            <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 IU rhFSH/150 IU rhLH after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>GONAL-f</title>
            <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Oocytes Retrieved</title>
          <description>Mean number of oocytes retrieved on the day of ovum pick up (OPU) was calculated. Oocyte retrieval was a technique used in in-vitro fertilization in order to remove oocytes from the ovary of the female, enabling fertilization outside the body.</description>
          <population>Intent-to-treat (ITT) analysis set included all subjects randomized who received at least 1 dose of GONAL-f or Pergoveris.</population>
          <units>oocytes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.71"/>
                    <measurement group_id="O2" value="3.6" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.054</p_value>
            <method>Poisson Regression Model</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.235</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4741</ci_lower_limit>
            <ci_upper_limit>0.003</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ongoing Pregnancy Rate</title>
        <description>Ongoing pregnancy rate was defined as the percentage of subjects with a ultrasound confirmation of at least one viable fetus (positive fetal heart beat).</description>
        <time_frame>70 days after embryo transfer (Day 185)</time_frame>
        <population>Modified intent-to-treat (MITT) analysis set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Pergoveris</title>
            <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 IU rhFSH/150 IU rhLH after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>GONAL-f</title>
            <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Ongoing Pregnancy Rate</title>
          <description>Ongoing pregnancy rate was defined as the percentage of subjects with a ultrasound confirmation of at least one viable fetus (positive fetal heart beat).</description>
          <population>Modified intent-to-treat (MITT) analysis set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.0"/>
                    <measurement group_id="O2" value="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Live Birth Rate</title>
        <description>Live birth rate was defined as the percentage of subjects with at least one live-born neonate.</description>
        <time_frame>Approximately 180 days following ongoing pregnancy determination (Day 365)</time_frame>
        <population>MITT analysis set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Pergoveris</title>
            <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 IU rhFSH/150 IU rhLH after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>GONAL-f</title>
            <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Live Birth Rate</title>
          <description>Live birth rate was defined as the percentage of subjects with at least one live-born neonate.</description>
          <population>MITT analysis set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.6"/>
                    <measurement group_id="O2" value="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Embryo Implantation Rate</title>
        <description>Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.</description>
        <time_frame>35-42 days post r-hCG administration (Day 154)</time_frame>
        <population>MITT analysis set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Pergoveris</title>
            <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 IU rhFSH/150 IU rhLH after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>GONAL-f</title>
            <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Embryo Implantation Rate</title>
          <description>Embryo implantation rate was measured as the number of gestational sacs observed divided by the number of embryos transferred multiplied by 100.</description>
          <population>MITT analysis set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration. Here &quot;Number of subjects analyzed&quot; signifies those subjects who were evaluable for this outcome measure.</population>
          <units>percent sacs per embryo</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="349"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.7"/>
                    <measurement group_id="O2" value="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Pregnancy Rate</title>
        <description>Clinical pregnancy rate defined as the percentage of subjects with a ultrasound confirmation of a gestational sac, with or without fetal heart activity.</description>
        <time_frame>35-42 days post r-hCG administration (Day 154)</time_frame>
        <population>MITT analysis set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Pergoveris</title>
            <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 IU rhFSH/150 IU rhLH after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>GONAL-f</title>
            <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Pregnancy Rate</title>
          <description>Clinical pregnancy rate defined as the percentage of subjects with a ultrasound confirmation of a gestational sac, with or without fetal heart activity.</description>
          <population>MITT analysis set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.1"/>
                    <measurement group_id="O2" value="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Biochemical Pregnancy Rate</title>
        <description>Biochemical pregnancy rate was defined as the percentage of subjects with a positive beta-hCG result from the serum pregnancy test.</description>
        <time_frame>15 to 20 days post r-hCG administration (Day 132)</time_frame>
        <population>MITT Analysis Set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration.</population>
        <group_list>
          <group group_id="O1">
            <title>Pergoveris</title>
            <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 IU rhFSH/150 IU rhLH after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
          </group>
          <group group_id="O2">
            <title>GONAL-f</title>
            <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
          </group>
        </group_list>
        <measure>
          <title>Biochemical Pregnancy Rate</title>
          <description>Biochemical pregnancy rate was defined as the percentage of subjects with a positive beta-hCG result from the serum pregnancy test.</description>
          <population>MITT Analysis Set included all randomized subjects who received at least 1 dose of GONAL-f or Pergoveris and did not have spontaneous pregnancy or death at approximately 34-38 hours after rhCG administration.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="462"/>
                <count group_id="O2" value="477"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.3"/>
                    <measurement group_id="O2" value="23.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline up to 180 days after ongoing pregnancy (maximum up to 365 days)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Pergoveris</title>
          <description>Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 IU rhFSH/150 IU rhLH after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject’s response per site standard clinical practice.</description>
        </group>
        <group group_id="E2">
          <title>GONAL-f</title>
          <description>GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject’s response per site standard clinical practice.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Fallot's tetralogy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Trisomy 21</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Premature labour</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperemesis gravidarum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Imminent abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Premature baby</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Premature delivery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Threatened labour</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ovarian cyst ruptured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ovarian haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ovarian rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="151" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia of pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ear swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Crying</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperthermia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Injection site haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Allergy to arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sinusitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vaginal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Body temperature increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Menstruation normal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nitrite urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urine ketone body</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Fluid retention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="58" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Restless legs syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abortion missed</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Abortion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Foetal death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Placenta praevia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vomiting in pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Depressive symptom</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Affective disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Libido increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Tearfulness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cystitis noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Dysmenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vaginal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Adnexa uteri pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dyspareunia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Uterine polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vulvovaginal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vulvovaginal pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nipple disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Premenstrual pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vaginal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vulvovaginal burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Vulvovaginal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Nasal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pityriasis rosea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Solar dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Abortion induced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="477"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="462"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="477"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Merck KGaA Communication Center</name_or_title>
      <organization>Merck Healthcare, a business of Merck KGaA, Darmstadt, Germany</organization>
      <phone>+49-6151-72-5200</phone>
      <email>service@merckgroup.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

